[Cerebrolysin with reperfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CEREHETIS trial].
Kalinin MN, Khasanova DR · 2025 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova; 2025
Study findings
The subgroup analysis associated Cerebrolysin with favorable day-14 imaging changes, including blood–brain barrier permeability and infarct volume.
- Population and setting
- CEREHETIS imaging subgroup: 16 treated and 17 controls
- Evidence type
- Human comparative study
- Preparation
- See the original report; formulation details require verification.
- Source language
- rus
- Title source
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
Study limitations
- Small subgroup and surrogate imaging endpoints.
- Same CEREHETIS program as other analyses; not independent replication.
- Full methods and risk of bias have not been independently assessed.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Related-report group: CEREHETIS. Reports in this group are not assumed to be independent trials.
Source access and review scope
Indexed record and available abstract checked; full text not reviewed.
Recorded source-check date: 2026-10-07. This date does not imply a completed systematic review.
Citation and original source
Original source: Kalinin MN, Khasanova DR. [Cerebrolysin with reperfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CEREHETIS trial]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova; 2025 2025.
Molekul research summary: https://molekul.io/research/cbl-update-40577185. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry